Welcome to the e-CCO Library!

search
Search by: 
Year: Category: Sub Type:
DOP72: Efficacy of tofacitinib dose escalation to 10 mg BID in patients with UC after completing maintenance therapy in remission and losing response: Data from OCTAVE open-label, long-term extension study
Year: 2020
Source: ECCO'20 Vienna
Authors: Julián Panés
Created: Tuesday, 23 June 2020, 5:40 PM
DOP72: HLA-DQA1*05 associates with immunogenicity and loss of response to anti-TNF therapy in the IBD population: A meta-analysis
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Elizabeth Spencer
Created: Friday, 14 July 2023, 2:22 PM
DOP72: Pregnancy for IBD-patients with an enterostomy is feasible but is associated with complications
Year: 2024
Source: ECCO'24 Stockholm
Authors: Bouwknegt, Dianne G.
Created: Tuesday, 30 April 2024, 5:03 PM
DOP72: Safety, tolerability and efficacy of anti-TL1A antibody PF-06480605 in treatment of Ulcerative Colitis: The open-label, multicentre, Phase 2a TUSCANY study
Year: 2020
Source: ECCO'20 Vienna
Authors: Silvio Danese
Created: Tuesday, 23 June 2020, 5:40 PM
DOP73: Early biological use in a Belgian, prospective inception cohort of patients with Inflammatory Bowel Disease: the PANTHER cohort
Year: 2024
Source: ECCO'24 Stockholm
Authors: Verstockt, Sare
Created: Tuesday, 30 April 2024, 5:03 PM
DOP73: Efficacy and safety of escalation to tofacitinib 10mg BID for patients with UC following loss of response on 5mg BID maintenance therapy: Results from OCTAVE open-label, long-term extension study
Year: 2020
Source: ECCO'20 Vienna
Authors: Alessandro Armuzzi
Created: Tuesday, 23 June 2020, 5:40 PM
Last Modified: Wednesday, 24 June 2020, 12:00 PM by Eloise Lanaud
DOP73: Predicting endoscopic improvement in Ulcerative Colitis using the Ulcerative Colitis Severity Index (UCSI)
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Neeraj Narula
Created: Friday, 14 July 2023, 2:22 PM
DOP74: Artificial Intelligence Quantifying Endoscopic Severity of Ulcerative Colitis in Gradation Scale
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Kaoru Takabayashi
Created: Friday, 14 July 2023, 2:22 PM
DOP74: Short and long-term effectiveness and safety of ustekinumab in Ulcerative Colitis in real life: the ULISES study
Year: 2024
Source: ECCO'24 Stockholm
Authors: Chaparro, María
Created: Tuesday, 30 April 2024, 5:03 PM
DOP74: Ustekinumab is associated with better effectiveness outcomes when compared to vedolizumab in Crohn's Disease patients with prior anti-TNF failure: Comparative effectiveness study from the ICC Registry
Year: 2020
Source: ECCO'20 Vienna
Authors: Marieke Pierik
Created: Tuesday, 23 June 2020, 5:40 PM
DOP75: Frequency and effectiveness of dose escalation of biologic therapy in Inflammatory Bowel Disease: The RAINBOW-IBD study of ENEIDA
Year: 2024
Source: ECCO'24 Stockholm
Authors: Rubín De Célix, Cristina
Created: Tuesday, 30 April 2024, 5:03 PM
DOP75: Video capsule endoscopy may detect active small bowel Crohn’s disease requiring change of treatment despite unremarkable ileo-colonic anastomosis
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Tamar Thurm
Created: Friday, 14 July 2023, 2:22 PM
DOP76: Comparison of healing of complex perianal Crohn´s disease fistulas by advancement flap and mesenchymal stem cell therapy
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Zuzana Serclova
Created: Friday, 14 July 2023, 2:22 PM
DOP76: Corticosteroid sparing effects of ustekinumab therapy for Ulcerative Colitis through 2 years: UNIFI long-term extension
Year: 2020
Source: ECCO'20 Vienna
Authors: Laurent Peyrin-Biroulet
Created: Tuesday, 23 June 2020, 5:40 PM
Last Modified: Wednesday, 24 June 2020, 12:03 PM by Eloise Lanaud
DOP76: Individual and comprehensive symptom resolution after induction and maintenance therapy with risankizumab in patients with moderately to severely active Ulcerative Colitis: A post-hoc analysis of INSPIRE and COMMAND studies
Year: 2024
Source: ECCO'24 Stockholm
Authors: Tinoco da Silva Torres, Joana
Created: Tuesday, 30 April 2024, 5:03 PM
DOP77: Is durable remission achievable after ileocolic resection for Crohn’s disease ? Long-term results of a prospective multicentric cohort study of the GETAID Chirurgie
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Solafah Abdalla
Created: Friday, 14 July 2023, 2:22 PM
DOP77: Mesenchymal stem cell therapy for refractory Crohn’s perianal fistulas: a case series
Year: 2024
Source: ECCO'24 Stockholm
Authors: Pronk, Annelies
Created: Tuesday, 30 April 2024, 5:03 PM
DOP78: Does KONO-S anastomosis reduce recurrence in Crohn's disease compared to conventional ileocolonic anastomosis ? A nationwide propensity score-matched study from GETAID Chirurgie Group (KoCoRICCO study).
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Zaher Lakkis
Created: Friday, 14 July 2023, 2:22 PM
DOP78: Efficacy of ozanimod by patient response trajectory subgroups identified using group-based trajectory modelling: a post hoc analysis of the phase 3 True North study
Year: 2024
Source: ECCO'24 Stockholm
Authors: Schreiber, Stefan Wolfgang
Created: Tuesday, 30 April 2024, 5:03 PM
DOP78: Intestinal surgery rates in Ulcerative Colitis and Crohn’s Disease in the era of biologics – A Danish Nationwide Register Study from 2003-2016
Year: 2020
Source: ECCO'20 Vienna
Authors: Niels Qvist
Created: Tuesday, 23 June 2020, 5:40 PM